Evidence map›Paper›PMID 25554368›Full record

ReviewThe American journal of medicine2015

Colchicine: old and new.

Anastasia Slobodnick, Binita Shah, Michael H Pillinger, Svetlana Krasnokutsky

Abstract readReview
In one paragraph

Review in The American journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Colchicine for the primary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  16. Article
  17. Article
  18. Harnessing endophytes and Multi-Omics for sustainable Colchicine biosynthesis.World journal of microbiology & biotechnology · 2026
    Review
  19. Article
  20. Review

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Anastasia SlobodnickDepartment of Medicine, VA New York Harbor Health Care System, New York; Division of Rheumatology, Department of Medicine, NYU School of Medicine/NYU Langone Medical Center, New York.
Binita ShahDepartment of Medicine, VA New York Harbor Health Care System, New York; Division of Cardiology, Department of Medicine, NYU School of Medicine/NYU Langone Medical Center, New York.
Michael H PillingerDepartment of Medicine, VA New York Harbor Health Care System, New York; Division of Rheumatology, Department of Medicine, NYU School of Medicine/NYU Langone Medical Center, New York. Electronic address: michael.pillinger@nyumc.org.
Svetlana KrasnokutskyDepartment of Medicine, VA New York Harbor Health Care System, New York; Division of Rheumatology, Department of Medicine, NYU School of Medicine/NYU Langone Medical Center, New York.

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
Institutional Clinical and Translational Science AwardUL1TR000038 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2012 to 2014
$16.8M
Institutional Career DevelopmentKL2TR001446 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PILLINGER, MICHAEL · 2015 to 2025
$6.7M
NCATS NIH HHS KL2 TR001446NCATS NIH HHS UL1 TR000038NCATS NIH HHS UL1TR000038NCATS NIH HHS UL1 TR001445
6 · The paper itself

Abstract

Although colchicine has been a focus of research, debate, and controversy for thousands of years, the US Food and Drug Administration just approved it in 2009. Over the past decade, advances in the knowledge of colchicine pharmacology, drug safety, and mechanisms of action have led to changes in colchicine dosing and to potential new uses for this very old drug. In this review, we discuss the pharmacologic properties of colchicine and summarize what is currently known about its mechanisms of action. We then discuss and update the use of colchicine in a variety of illnesses, including rheumatic and, most recently, cardiovascular diseases.

Indexed as

ColchicineCytochrome P-450 CYP3ADrug InteractionsFamilial Mediterranean FeverGout SuppressantsHeart DiseasesHumansPericarditisRheumatic DiseasesVascular DiseasesColchicineCytochrome P-450 CYP3AGout SuppressantsCardiovascular diseaseColchicineGoutInflammation

Identifiers

PMID25554368
PMCPMC4684410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.